Find Approved Immunology Drugs in Clinical Development

Lead Product(s): Human Immune Globulin

Therapeutic Area: Immunology

Highest Development Status: Approved Product Type: Large molecule

Partner/Sponsor/Collaborator: Morgan Stanley

Deal Size: $94.6 million Upfront Cash: Undisclosed

Deal Type: Public Offering February 24, 2020

Details:

ADMA intends to use the net proceeds from this offering (i) for the procurement of raw materials for the manufacturing of BIVIGAM and ASCENIV.

Lead Product(s): Human Immune Globulin

Therapeutic Area: Immunology

Highest Development Status: Approved Product Type: Large molecule

Partner/Sponsor/Collaborator: Morgan Stanley

Deal Size: $82.3 million Upfront Cash: Undisclosed

Deal Type: Public Offering February 06, 2020

Details:

ADMA intends to use the net proceeds to procure raw materials for the production of BIVIGAM and ASCENIV, to support their marketing and other corporate purposes.

Lead Product(s): Peanut (Arachis hypogaea) Allergen-dnfp

Therapeutic Area: Immunology

Highest Development Status: Approved Product Type: Large molecule

Partner/Sponsor/Collaborator: Nestle Health Science

Deal Size: $473.0 million Upfront Cash: Undisclosed

Deal Type: Investment February 05, 2020

Details:

Nestle Health Science's investment in Aimmune is intended to help assure PALFORZIA’s longer-term commercial success and allow Aimmune to continue making progress in food allergy treatments.

Lead Product(s): Adalimumab

Therapeutic Area: Immunology

Highest Development Status: Approved Product Type: Large molecule

Partner/Sponsor/Collaborator: Samsung Bioepis

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Partnership January 16, 2020

Details:

The partnership covers Samsung Bioepis’ biosimilar candidates in the field of immunology and oncology, including SB5 (adalimumab), SB4 (etanercept), SB3 (trastuzumab), and SB8 (bevacizumab).